Inclusion Criteria:  Pathological diagnosis of NSCLC with confirmed activation of driver gene mutation (EGFR mutant: exon 19 deletion or exon 21 L858R mutation; ALK-rearrangement) by amplification refractory mutation system (ARMS); stage IIIB-IV according to the eighth edition of the American Joint Committee on Cancer staging system confirmed by pathological diagnosis and positron emission tomography-computed tomography (PET-CT) and biopsy Written informed consent provided； Age 18-70 when signing the consent form, both male and female; The ECOG score is 0 or 1; Adequate hematological function, liver function and renal function; Female participants should not be pregnant or breast-feeding.  Exclusion Criteria:  Previously received systemic anti-tumor therapy for non-small cell lung cancer; Subjects who have received chest radiotherapy in the past; Known human immunodeficiency virus (HIV) infection; Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease); Pregnancy or breast-feeding women; Ingredients mixed with small cell lung cancer patients.